Home/Business/Companies/Zydus Lifesciences Q2 FY27 profit falls …

Zydus Lifesciences Q2 FY27 profit falls from Q1 FY27

Companies
By ThePip Desk••
Add as a preferred source on Google
Zydus Lifesciences Q2 FY27 results

Key Highlights

Zydus Lifesciences Q2 FY27 results show a net profit of ₹928 crore. Revenue from operations for the quarter was ₹7,910 crore.

Updated: Wednesday 4 November 2026

  • Zydus Lifesciences reported a net profit of ₹928 crore in Q2 FY27, 25.10% lower than a year earlier.
  • from operations: ₹7,910 crore, 29.17% higher than a year earlier.
  • Net profit margin: 11.73% (20.23% a year earlier).
  • Shares: ₹1,188.10, −4.23% at 15:31 IST on 4 Nov 2026.

Zydus Lifesciences Q2 FY27 results show a net profit of ₹928 crore, which is 25.10% lower than a year earlier. The company filed these results on 4 November 2026 at 12:24 pm IST.

Revenue from operations for the quarter reached ₹7,910 crore. This figure is 29.17% higher than the same quarter a year ago.

Zydus Lifesciences Q2 FY27 results at a glance

Zydus Lifesciences Q2 FY27 results (quarter ended 30 September 2026, consolidated) — Source: company results
₹ croreQ2 FY27Q2 FY26ChangeQ1 FY27Change
Revenue from operations7,9106,123+29.17%8,017−1.34%
1,2621,693−25.46%1,344−6.15%
Net profit9281,239−25.10%990−6.31%
Earnings per share₹9.27₹12.51−25.88%₹9.42−1.52%
Net profit as a share of revenue11.73%20.23%–12.35%–

The company reported a profit before tax of ₹1,262 crore for the quarter. Net profit as a share of revenue was 11.73%, compared to 20.23% in Q2 FY26 and 12.35% in Q1 FY27. For the half-year ending 30 September 2026, the company recorded a net profit of ₹1,939 crore, which is 29.75% lower than the same period a year earlier.

Zydus Lifesciences net profit, last 5 quarters
Zydus Lifesciences’s net profit over its last 5 reported quarters (₹ crore).

Zydus Lifesciences half-year figures

Zydus Lifesciences half-year to 30 September 2026 (consolidated) — Source: company results
₹ croreHalf-yearSame period a year earlierChange
Revenue from operations15,92712,697+25.44%
Net profit1,9392,760−29.75%

Zydus Lifesciences share price after the results

Zydus Lifesciences share price on Wednesday 4 November 2026 — Source: prices; The results were filed at 12:24 IST, during the session; the move is from the previous close, so it includes trading before the filing.
Share price (15:31 IST)₹1,188.10
Previous close₹1,240.60
Change−₹52.50 (−4.23%)
Nifty Pharma+0.42%
+0.63%

The share price of Zydus Lifesciences Ltd. closed at ₹1,188.10 on 4 November 2026. This represents a move of −4.23% from the previous close of ₹1,240.60. The company filed its results at 12:24 pm IST during the trading session.

How Zydus Lifesciences shares moved on its earlier results

Zydus Lifesciences share price on its earlier results — from the last close before the filing to the next close; Source: NSE prices, filings
QuarterResults filedWindowChange
Q1 FY2711 Aug 202610 Aug 2026 to 11 Aug 2026+6.43%
Q4 FY2619 May 202618 May 2026 to 19 May 2026+2.80%

The share price moved by +6.43% between 10 August 2026 and 11 August 2026 for Q1 FY27. The stock price moved by +2.80% between 18 May 2026 and 19 May 2026 for Q4 FY26.

Zydus Lifesciences Q2 FY27 results: FAQs

What were Zydus Lifesciences’s Q2 FY27 results?

Zydus Lifesciences reported a net profit of ₹928 crore and revenue from operations of ₹7,910 crore for the quarter ended 30 September 2026 (consolidated figures). Net profit was 25.10% lower than a year earlier and revenue from operations was 29.17% higher than a year earlier.

When did Zydus Lifesciences announce its Q2 FY27 results?

The results were filed with the exchange at Wed 4 Nov, 12:24 pm IST.

What was Zydus Lifesciences’s net profit margin in Q2 FY27?

Net profit was 11.73% of revenue, against 20.23% in the same quarter a year earlier.

What is the Zydus Lifesciences share price after the results?

₹1,188.10, −4.23% from the previous close of ₹1,240.60, at 15:31 IST on Wednesday 4 November 2026. The results were filed at 12:24 IST, during the session; the move is from the previous close, so it includes trading before the filing.

Results are the company’s filings to the exchanges; prices are from the National Stock Exchange. Calculations are by ThePip. For information only; not investment advice.